Founded in 2018, TigerGene is a venture capital firm based in Cambridge, Massachusetts. The firm seeks to invest in companies operating in life science technology and platform technology companies.
NanoMosaic specializes in innovative solutions for early illness detection, prognostic monitoring, and biomarker identification. The company has developed a unique platform that utilizes nanoneedles for protein detection and quantification. This technology facilitates the analysis of multiple biomarkers on a single chip, making it possible for the medical and healthcare sectors to enhance the speed and accuracy of biomarker discovery and validation. By enabling more efficient proteomic analysis, NanoMosaic aims to improve early disease detection and monitoring, ultimately contributing to better health outcomes.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.